Cardiomyopathy Linked to Faulty Regulation of Heart Protein Succinylation
|
By LabMedica International staff writers Posted on 28 Apr 2016 |

Image: A model of the structure of the SIRT5 protein (Photo courtesy of Wikimedia Commons).
The enzyme SIRT5, also known as sirtuin (silent mating type information regulation 2 homolog) 5, was found to play a critical role in maintaining healthy cardiac function by regulating the lysine succinylation modification of heart cell proteins.
Lysine succinylation is a recently discovered protein posttranslational modification (PTM), and SIRT5 is an efficient desuccinylase enzyme. Although many mammalian proteins have been found to be regulated by lysine succinylation and SIRT5, the physiological significance of succinylation and SIRT5 remains unknown.
To better understand the consequences of protein succinylation, investigators at Cornell University (Ithaca, NY, USA) and their colleagues at Ecole Polytechnique Fédérale de Lausanne (Switzerland) profiled acyl-CoA molecules in various mouse tissues. They discovered that different tissues had different acyl-CoA profiles and that succinyl-CoA was the most abundant acyl-CoA molecule in the heart. This observation prompted them to examine protein lysine succinylation in different mouse tissues in the presence and absence of SIRT5.
The investigators reported in the April 5, 2016, online edition of the journal Proceedings of the [U.S.] National Academy of Sciences that protein lysine succinylation predominantly accumulated in the heart in mice that had been genetically engineered to lack the gene for Sirt5. Using proteomic studies, they were able to identify many cardiac proteins regulated by SIRT5.
In particular, they found that ECHA (also known as HADHA or hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional protein), alpha subunit), a protein involved in fatty acid oxidation, was a major enzyme that was regulated by SIRT5 and affected heart function. Sirt5 knockout (KO) mice had lower ECHA activity, increased long-chain acyl-CoAs, and decreased ATP in the heart under fasting conditions. On the physiological level, it was found that Sirt5 KO mice developed hypertrophic cardiomyopathy, as evident from the increased heart weight relative to body weight in these animals.
"Our research suggests that perhaps one way to improve heart function is to find a way to improve SIRT5 activity," said senior author Dr. Hening Lin, professor of chemistry and chemical biology at Cornell University.
"The identification of this new role of SIRT5 in cardiomyopathy assigns an important role of this druggable enzyme in one of the major cardiac diseases," said contributing author Dr. Johan Auwerx, professor of energy metabolism at the Ecole Polytechnique Fédérale de Lausanne. "It can be expected that pharmacological interference with these pathways will lead to new therapies for cardiomyopathy that, as such, can extend healthy life span."
Related Links:
Cornell University
Ecole Polytechnique Fédérale de Lausanne
Lysine succinylation is a recently discovered protein posttranslational modification (PTM), and SIRT5 is an efficient desuccinylase enzyme. Although many mammalian proteins have been found to be regulated by lysine succinylation and SIRT5, the physiological significance of succinylation and SIRT5 remains unknown.
To better understand the consequences of protein succinylation, investigators at Cornell University (Ithaca, NY, USA) and their colleagues at Ecole Polytechnique Fédérale de Lausanne (Switzerland) profiled acyl-CoA molecules in various mouse tissues. They discovered that different tissues had different acyl-CoA profiles and that succinyl-CoA was the most abundant acyl-CoA molecule in the heart. This observation prompted them to examine protein lysine succinylation in different mouse tissues in the presence and absence of SIRT5.
The investigators reported in the April 5, 2016, online edition of the journal Proceedings of the [U.S.] National Academy of Sciences that protein lysine succinylation predominantly accumulated in the heart in mice that had been genetically engineered to lack the gene for Sirt5. Using proteomic studies, they were able to identify many cardiac proteins regulated by SIRT5.
In particular, they found that ECHA (also known as HADHA or hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional protein), alpha subunit), a protein involved in fatty acid oxidation, was a major enzyme that was regulated by SIRT5 and affected heart function. Sirt5 knockout (KO) mice had lower ECHA activity, increased long-chain acyl-CoAs, and decreased ATP in the heart under fasting conditions. On the physiological level, it was found that Sirt5 KO mice developed hypertrophic cardiomyopathy, as evident from the increased heart weight relative to body weight in these animals.
"Our research suggests that perhaps one way to improve heart function is to find a way to improve SIRT5 activity," said senior author Dr. Hening Lin, professor of chemistry and chemical biology at Cornell University.
"The identification of this new role of SIRT5 in cardiomyopathy assigns an important role of this druggable enzyme in one of the major cardiac diseases," said contributing author Dr. Johan Auwerx, professor of energy metabolism at the Ecole Polytechnique Fédérale de Lausanne. "It can be expected that pharmacological interference with these pathways will lead to new therapies for cardiomyopathy that, as such, can extend healthy life span."
Related Links:
Cornell University
Ecole Polytechnique Fédérale de Lausanne
Latest BioResearch News
- Innate Immunity Variants Associated With Earlier Breast Cancer in BRCA1 Carriers
- Genetic Cause Identified for Severe Infant Epilepsy
- Study Reveals Diagnostic and Therapeutic Target in Rare Pancreatic Tumors
- Researchers Identify Survival Pathway Undermining Targeted Cancer Drugs
- Large-Scale Study Maps DNA Damage Signatures Across Multiple Cancers
- Study Identifies Distinct Immune Signatures to Early Depression and Psychosis
- Genetic Mutation Behind Aggressive Adult Leukemia Offers Treatment Clues
- Disease Gene Discovery Advances Diagnosis of Rare Movement Disorders
- Genetic Discovery Could Improve Diagnosis of Drug-Resistant Epilepsy
- Genetic Discovery May Improve Diagnosis of Rare Dementia Subtype
- Mass Spectrometry Technique Detects Protein and Sugar Changes in Neurodegeneration
- Barcoded DNA Sheds Light on Hidden Complexities in Breast Cancer Detection
- CRISPR-Based Platform Pinpoints Drivers of Acute Myeloid Leukemia in Patient Cells
- Protective Brain Protein Emerges as Biomarker Target in Alzheimer’s Disease
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
Channels
Clinical Chemistry
view channel
AI-Based Blood Test Diagnose Multiple Brain Disorders from Blood Sample
Diagnosing the cause of age-related cognitive symptoms remains challenging because clinical presentations of neurodegenerative diseases often overlap, and multiple pathologies can co-occur... Read more
New CLIA Status Brings Mass Spectrometry Steroid Testing to Routine Labs
Steroid hormone measurement is a core application of clinical mass spectrometry, which is widely regarded as a diagnostic gold standard. Access to these high-specificity methods has often been constrained... Read moreMolecular Diagnostics
view channel
RNA Profiling Uncovers Therapeutic Targets in Solid Tumors
Many patients with advanced solid tumors exhaust broad DNA panel testing yet still lack biomarkers that match guideline-recommended therapies, limiting access to targeted options. Expanding molecular profiling... Read more
Whole Genome Sequencing in Routine Care Expands Rare Disease Detection
Rare diseases often involve prolonged diagnostic journeys that delay clinical decision-making and complicate family planning. As phenotypes become more heterogeneous, sequencing-based methods are increasingly... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
New Bacterial Target Identified for Early Detection of Noma
Noma is a rapidly progressing orofacial infection that begins as gingivitis and can destroy oral and facial tissues, primarily affecting young children living in extreme poverty. Without treatment, it... Read more
Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
Streptococcus dysgalactiae subspecies equisimilis (SDSE) infections are increasing worldwide and include variants that may lead to severe disease. Researchers now report that whole-genome sequencing of... Read morePathology
view channel
AI Tool Predicts Patient-Specific Chemotherapy Benefit in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer is typically guided by recurrence risk and population-level averages rather than patient-specific benefit. However, existing clinicopathologic... Read more
AI-Based Pathology Model Guides Chemotherapy Decisions in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer remains a difficult decision because only a subset benefits and many undergo toxicity without gain. Genomic assays can help but are costly,... Read moreTechnology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channel
Takara Bio USA and Hamilton Partner Partner to Automate NGS Library Preparation
Takara Bio USA, Inc. (San Jose, CA, USA), a wholly owned subsidiary of Takara Bio Inc., and Hamilton Company (Reno, NV, USA) announced a development and co-marketing agreement to deliver integrated, automated... Read more








